Integra LifeSciences Makes Strides in ESG Strategy
Integra LifeSciences Holding Company (NASDAQ: IART), a prominent global medical technology firm, has released its latest Environmental, Social, and Governance (ESG) report. This document highlights the company's ESG performance for 2023 and outlines its ongoing commitment to the ESG strategy and roadmap established three years ago.
Innovation as a Catalyst for Change
“Our commitment to innovating treatment pathways to enhance patient outcomes and establish new standards of care is a priority for our Integra colleagues worldwide. This drive fuels our efforts every single day,” said Jan De Witte, president and chief executive officer of Integra LifeSciences. The company's dedication to enhancing its ESG initiatives is clear as they work to create healthier environments and communities.
Notable Highlights from the ESG Report
Integra’s ESG report showcases significant progress in key areas over the past year, underscoring the company’s resolve to fulfill its ESG commitments.
Environmental Efforts
Regarding environmental impact, Integra has recalibrated its Scope 1, 2, and 3 emissions. In partnership with an external consultant, the company performed comprehensive energy assessments at its highest energy-consuming locations. This initiative aims to identify opportunities for energy reduction to improve their greenhouse gas footprint.
Social Responsibility Initiatives
On the social responsibility front, Integra has bolstered its diversity and inclusion efforts by launching a new employee resource group. Additionally, the company has increased its focus on supporting early-career talent, providing valuable resources and hands-on experience to diverse college students and graduates, thereby nurturing an inclusive workplace.
Enhancements in Governance
From a governance standpoint, Integra has updated its Code of Conduct and continued to strengthen its anti-bribery and corruption program through ongoing training initiatives. These actions reflect the company's commitment to upholding high governance standards.
Alignment with Global Standards
Integra prepared its ESG report in accordance with various external guidelines and measurement frameworks, including the Global Reporting Index and the Sustainability Accounting Standards Board Index. This alignment ensures that their ESG performance remains transparent and comparable to industry benchmarks.
Dedication to Stakeholders
Integra is driven by a purpose centered on restoring patients’ lives. The company consistently innovates treatment pathways to enhance patient outcomes while setting new standards in surgical, neurologic, and regenerative care. Integra's comprehensive portfolio features high-quality, leading brands designed for optimal patient care.
For the latest insights and information on Integra and its innovative products, stakeholders are encouraged to visit investor.integralife.com.
Contact Information
Contacts:
Investors:
Chris Ward
(609) 936-2322
chris.ward@integralife.com
Media:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
Frequently Asked Questions
What is the primary focus of Integra LifeSciences' ESG report?
The ESG report emphasizes the company's environmental, social, and governance practices, highlighting achievements and future commitments.
How does Integra approach environmental sustainability?
Integra adopts a proactive stance by recalibrating emissions and evaluating energy consumption to identify reduction opportunities.
What initiatives has Integra implemented for social responsibility?
Integra has improved its diversity efforts and created support systems for early-career talent and diverse college students.
What governance practices has Integra strengthened?
The company has updated its Code of Conduct and enhanced training programs focused on anti-bribery and corruption.
Where can stakeholders find more information about Integra?
Stakeholders can visit investor.integralife.com for the latest news and updates regarding the company and its products.